Investors and analysts may pick at Tandem Diabetes' decline in international pump shipments or the timing of t:sport launch but they would be ignoring the "unmistakable momentum" in the company's overall performance, Lake Street analyst Brooks O'Neil tells investors in a post-earnings research note titled "Don't Make A Mountain Out Of a Molehill. Continued Execution and Innovation Expected." International markets "represent enormous opportunity, but are on a different cadence than the U.S. market," contends the analyst. He notes that Tandem is entering Germany, France, and the Benelux countries now, which will double its international footprint during 2020. O'Neil expects "robust" international growth this year and reiterates a Buy rating on Tandem Diabetes with a $100 price target.